A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 5,45 (+127,08%). A mediana é € 5,45 (+127,08%).
| Comprar |
6 |
| Manter |
0 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Anixa Biosciences: two clinical cancer programs show encouraging early data
At the H.C. Wainwright conference, Anixa Biosciences presented positive early data for its CAR‑T program in ovarian cancer (14 patients treated; one survived 28 months, several >1 year vs expected ~12 weeks) and for a breast cancer vaccine that completed phase I with 35 patients and showed immune responses in ~75%. The company has $14M in cash, an annual burn rate of $5–7M, is debt‑free, and plans to out‑license both programs to partners after clinical success rather than build a large commercial infrastructure. Next clinical steps are dose escalation for the CAR‑T and moving the vaccine into phase II with a randomized neoadjuvant design. » Mais em de.investing.com
Anixa has treated first patient in fifth cohort with highest CAR‑T dose in ovarian cancer
Anixa has treated the first patient in the fifth cohort of its Phase 1 study at Moffitt Cancer Center with 1×10^7 CAR‑positive cells/kg, the highest dose level tested to date. No dose‑limiting toxicities were observed at the previous dose level (3×10^6/kg). The Lira‑Cel therapy targets the follicle‑stimulating hormone receptor and has shown long‑term survival of up to more than two years in some patients. The stock recently rose 14.7% to $3.27, with a market capitalization of $111 million. » Mais em de.investing.com
Anixa secures patent for breast cancer vaccine in South Korea
The Korean Intellectual Property Office granted Anixa the patent (No. 10-2960889) for its breast cancer vaccine technology, providing protection in South Korea until 2040. The technology, exclusively licensed from the Cleveland Clinic, aims at prevention and treatment by immunization against human α-Lactalbumin. A phase‑1 study met all primary endpoints, was safe, well tolerated and showed an immune response in 74% of participants. Anixa remains clinically unbalanced but has more liquid assets than debt; analysts see price targets of $7–14 versus the current level of about $2.79. » Mais em de.investing.com
Anixa Biosciences receives patent in Mexico for breast cancer vaccine
The Mexican Institute of Industrial Property has granted Anixa Biosciences a patent (No. 432748) covering key aspects of its breast cancer vaccine targeting α-lactalbumin, protecting the technology in Mexico until 2040. The vaccine, licensed exclusively from the Cleveland Clinic, met primary endpoints in a phase‑1 trial, showed good tolerability and elicited immune responses in 74% of participants; a phase‑2 study is being prepared. According to its balance sheet, Anixa has more cash than debt and strong short-term liquidity; analysts set price targets between $9 and $14 versus a current share price of $3.01. » Mais em de.investing.com
Anixa presents phase‑1 data on CAR‑T therapy Lira‑Cel at ISCT meeting
Anixa announced that a presentation on the ovarian cancer therapy Lira‑Cel will be given at the annual meeting of the International Society for Cell & Gene Therapy. Cheryl Cox from the Moffitt Cancer Center will report on the study design, objectives and the current status of the ongoing phase‑1 trial (NCT05316129) in patients with recurrent ovarian cancer after at least two prior therapies. Lira‑Cel is an FSHR‑targeting CAR‑T/CER‑T therapy being developed in collaboration with the Moffitt Cancer Center; Anixa remains in the clinical stage, is not profitable, has more cash than debt, and has analyst price targets between $9 and $14. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | julho de 2026 | YoY |
|---|---|---|
| Receitas | 0 | - |
| Ganho bruto | -8,67 mil | - |
| Ganho líquido | -2,26 mi | 14,28% |
| EBITDA | -2,36 mi | 18,90% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 82,77 mi |
Número de ações | 34,76 mi |
Máximo/mínimo de 52 semanas | € 4,96 - € 2,11 |
| Dividendos | Não |
Beta | 0,60 |
PER (PE Ratio) | -8,59 |
PEG (PEG Ratio) | 0,01 |
P/VC (PB Ratio) | 6,19 |
P/V (PS Ratio) | 0,00 |
Perfil da empresa
A Anixa Biosciences, Inc., uma empresa de biotecnologia, desenvolve terapias e vacinas focadas em necessidades médicas críticas não satisfeitas nas áreas da oncologia e das doenças infeciosas. Os programas de terapêuticas da empresa incluem o desenvolvimento de uma tecnologia de linfócitos T com recetor endócrino quimérico, uma nova forma de tecnologia de linfócitos T com recetor de antigénio quimérico (CAR-T) focada no tratamento do cancro do ovário; e a descoberta e o desenvolvimento de candidatos a fármacos antivíricos para o tratamento da COVID-19, focados na inibição de determinadas funções proteicas do vírus. Os seus programas de vacinas incluem o desenvolvimento de uma vacina contra o cancro da mama triplo negativo; e uma vacina preventiva contra o cancro do ovário. A empresa também está a desenvolver fármacos de imunoterapia contra o cancro. Tem um acordo de colaboração com a MolGenie GmbH para descobrir e desenvolver candidatos a fármacos antivíricos contra a COVID-19. A empresa era anteriormente conhecida como ITUS Corporation e mudou o seu nome para Anixa Biosciences, Inc. em outubro de 2018. A Anixa Biosciences, Inc. foi constituída em 1982 e tem sede em San Jose, Califórnia.
| Nome | ANIXA Biosciences Inc |
| CEO | Amit Kumar |
| Sede | San Jose,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Biotecnologia |
| Entrada em bolsa | 07/10/1983 |
| Colaboradores | 4 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | ANIX |
Frankfurt | CY71.F |
Düsseldorf | A2N6ZF.DU |
München | A2N6ZF.MU |